Literature DB >> 8119664

Renal catabolism of truncated glucagon-like peptide 1.

C Ruiz-Grande1, C Alarcón, A Alcántara, C Castilla, J M López Novoa, M L Villanueva-Peñacarrillo, I Valverde.   

Abstract

We have searched for the contribution of the kidney to the catabolism of glucagon-like peptide-1 (7-36)amide or tGLP-1 by analyzing the disappearance of the [125I]tGLP-1 both in vivo, from the plasma of bilaterally nephrectomized (BNX), ureteral-ligated (BUL) and normal rats and in vitro from the perfusate of an isolated rat kidney system. Also, we have measured the degradation of the peptide by the isolated renal tubules. Results from in vivo studies demonstrated that the disappearance half-time (t1/2) of [125I]tGLP-1 was significantly lower in the control than in BUL or BNX rats with the metabolic clearance rate (MCR) being higher in the control than in BUL and BNX group; no difference was found for both parameters between BUL and BNX rats. The urinary excretion of the peptide was negligible. The data from the isolated kidney experiments showed a disappearance of the peptide, which was not due to its spontaneous degradation nor to enzymes released from the kidney to the perfusate. Degradation of the peptide also occurred in the presence of isolated tubules. It was dependent upon the concentration of tubules. This could possibly be due to the action of the brush border-associated peptidases. In conclusion, our results demonstrate that, in the rat, the kidney removes the exogenous tGLP-1 from the peripheral circulation, by a mechanism that involves glomerular filtration and tubular catabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119664     DOI: 10.1055/s-2007-1002190

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  15 in total

1.  Antidiabetogenic action of truncated glucagon-like peptide-1 in mice.

Authors:  B Ahrén
Journal:  Endocrine       Date:  1995-05       Impact factor: 3.633

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 3.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 4.  Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.

Authors:  Jaime A Davidson
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  Role and development of GLP-1 receptor agonists in the management of diabetes.

Authors:  Chee W Chia; Josephine M Egan
Journal:  Diabetes Metab Syndr Obes       Date:  2009-05-15       Impact factor: 3.168

7.  Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients.

Authors:  Anna Masajtis-Zagajewska; Ilona Kurnatowska; Małgorzata Wajdlich; Marta Jagodzińska; Michał Nowicki
Journal:  Int Urol Nephrol       Date:  2013-05-14       Impact factor: 2.370

8.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.

Authors:  P A Velasquez-Mieyer; P A Cowan; G E Umpierrez; R H Lustig; A K Cashion; G A Burghen
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

Review 9.  Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Authors:  Guojing Luo; Hong Liu; Hongyun Lu
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

Review 10.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.